Compare Main Street Capital Corporation (MAIN) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Novavax Inc — how do they compare? Main Street Capital Corporation trades at $54.47 (market cap $5.07B), while Novavax Inc trades at $11 (market cap $1.85B). The key difference: Main Street Capital Corporation is far larger — about 2.7× Novavax Inc's market cap, and Main Street Capital Corporation pays a 5.87% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Main Street Capital Corporation for 88 Days and Novavax Inc for 59 Days on average.
| MAIN | NVAX | |
|---|---|---|
Market Cap | $5.07B | $1.85B |
Volume | 685,683 | 8,362,562 |
Sector | Financials | Health |
52-Week High | $64.60 | $12.56 |
52-Week Low | $49.63 | $6.22 |
Typical Hold Time | 88 Days | 59 Days |
Enterprise Value | $7.51B | $1.43B |
Dividend Yield | 5.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.18, down 1.08% on the day, with a bearish technical signal from moving averages and oscillators. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while maintaining strong profitability with an 80.77% net income margin. Recent news highlights MAIN's status as a top-tier BDC with a well-covered monthly dividend, though some analysts cite valuation concerns amid rising Treasury yields.
Outlook remains cautiously optimistic given MAIN's robust fundamentals and dividend track record, but near-term headwinds include earnings volatility and premium valuation risks. The stock offers income appeal with a 7.9%+ yield, yet investors face pressure from technical weakness and macroeconomic sensitivity.
Novavax (NVAX) trades at $11.01, down 2.74% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported strong revenue of $1.12B in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Recent news highlights the company's pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in major markets.
Investment outlook remains speculative with analyst consensus heavily favoring Buy ratings (73.92%) but fundamental risks persist including negative cash flow trends and high debt levels. The stock offers potential upside from partnership expansions but faces significant execution and competitive risks in the biopharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
